Can an existing drug calm the itch of rare genetic skin diseases?
NCT ID NCT05649098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing whether dupilumab, a drug already used for eczema, can reduce severe itching in people with various genetic skin disorders. The trial will enroll 30 participants and last 26 months, including a 16-week treatment period and a longer extension phase. The main goal is to see if itch scores improve significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab
- What this could lead to
- If it works, this could point toward a new way to ease severe itching in hard-to-treat genetic skin conditions.
- What could go wrong
- This is a very early, small pilot study with only 30 people. It may not show clear benefit, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your daily commute be drying out your skin?
- Gene therapy gel targets rare blistering skin disease
- Scientists probe UV's hidden immune trick in skin
- New imaging tool may help detect Eye-Area skin cancer without a biopsy
- AI reads your symptom stories to find hidden medical clues
- App vs. phone: which triage method guides patients better?